Lantos A, Tarján E, Várnai Z, Zsiray M
Department of Pulmonology, Semmelweis University Medical School, Budapest.
Ther Hung. 1993;41(4):146-9.
The effect of 2 sodium chromoglycate products: Taleum 1-mg aerosol (EGIS) and Intal powder capsule (Fisons) has been examined for 4-4 weeks in 15 extrinsic asthma patients by cross-over self-controlled open method. The patients measured peak expiratory flow (PEF) 5 times daily and recorded the time of dyspneic periods in a diary as well as the amount of bronchodilator spray (Berodual, Boehringer) used as adjuvant therapy during dyspnea. The results of the weekly evaluation of the complaints and PEF values proved that both drugs are similarly effective in the prevention of dyspnea caused by bronchial asthma. The adjuvant inhalation betamimetic and anticholinergic drug requirement was lowered, the number, intensity and total time of dyspneic episodes decreased. In the course of the examinations Taleum 1-mg inhalation aerosol proved to be of identical value with Intal powder capsule. Some patients who do not like powder inhalation found the Taleum aerosol drug form to be more advantageous. Side-effect of drug was not observed.
对15名外源性哮喘患者采用交叉自身对照开放法，对两种色甘酸钠产品（1毫克的Taleum气雾剂（匈牙利吉瑞大药厂）和因他粉胶囊（费森斯公司））进行了为期4周的疗效研究。患者每天测量5次呼气峰值流速（PEF），并在日记中记录呼吸困难发作的时间，以及在呼吸困难期间用作辅助治疗的支气管扩张剂喷雾（贝罗都尔，勃林格殷格翰公司）的用量。对症状和PEF值的每周评估结果证明，两种药物在预防支气管哮喘引起的呼吸困难方面同样有效。辅助吸入β-拟交感神经药和抗胆碱能药物的需求降低，呼吸困难发作的次数、强度和总时间减少。在检查过程中，1毫克的Taleum吸入气雾剂被证明与因他粉胶囊具有相同的价值。一些不喜欢吸入粉剂的患者发现Taleum气雾剂剂型更具优势。未观察到药物的副作用。
